About this trial
The primary purpose of this study is to determine if there are significant differences with respect to baseline between those randomized to CGo and standard-of-care versus standard-of-care alone after completing 12-weeks of therapy in terms of peripheral endothelial function measured by EndoPAT.
Eligibility criteria
Qualifiers
18 years of age or older
Ability to use the CamliGo device for 12-weeks
Willingness to complete study questionnaires, blood tests,& EndoPat testing at the beginning and end of study
Patients who have had a recent MI who will be undergoing clinically indicated Cardiac Rehabilitation
Disqualifiers
Cognitively impaired patients
Patient with Bipolar disorder, psychosis or delusional disorder
History of substance abuse or dependence
History of suicidality
Trial design
Treatments tested in this trial
- CalmioGO Stress management device
Treatment groups
Locations
1Sponsors and collaborators
Mayo Clinic
Lead sponsor
CalmiGO
Collaborator